Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

In a welcome surprise, China plans to deep-six price caps on drugs

Some good news for emerging-market ambitions: China is backpedaling on price caps. After shortages prompted the government to ease up on certain price controls earlier this year, officials are now preparing to lift the price controls as early as Jan. 1.

With Duaklir nod in EU, AstraZeneca scores first new drug from Almirall buyout

With the EU approval of COPD med Duaklir, AstraZeneca is getting exactly what it wanted when it sealed a deal for Almirall's respiratory portfolio earlier this month. The only problem? Calling the market crowded is an understatement.

Takeda's U.S. chief bows out amid management shake-up

When Takeda Pharmaceutical faced the patent-cliff blues, it brought in Christophe Weber as president and COO to engineer a revamp. And true to his mission, Weber unveiled a new org chart in September, along with a fresh set of top managers.

Novo Nordisk shrinks executive team as top-ranking woman leaves

Novo Nordisk says it has reorganized its executive team, with EVP Lise Kingo making an exit and her duties divvied up among the company's remaining top execs.

Drug prices plus low reimbursements force cancer docs to sell out

Rising cancer drug prices aren't just alarming to payers. They're squeezing oncologists, too, at a time when doctors are paid less to administer drugs--to the point where they're selling out to hospitals.

Can Sanofi parlay low Lantus prices into Toujeo sales? That's the billion-dollar question

It was Sanofi's first public event without ex-CEO Chris Viehbacher. But the French drugmaker's investor day didn't bring much in the way of surprise. As expected, Sanofi Chairman Serge Weinberg talked up the launches expected for next year and beyond, all $38 billion worth.

France strikes big hep C treatment deal for Gilead's Sovaldi

France threatened to tax hepatitis C drugmakers if they insisted on charging nosebleed prices. Apparently, the arm-twisting worked: The French government says it has cut a deal with Gilead Sciences to get Sovaldi at the lowest price in Europe.

So long, patent cliff. Hello, hep C and cancer. Welcome to $1.3T in global drug spending

What happens when the worst of the pharma patent cliff passes and new drug approvals surge? A big leap in drug spending. After a sluggish 5 years or so, global outlay on pharma products will jump by up to 30%--or $335 billion--by 2018, according to a new report from the IMS Institute of Healthcare Informatics.

Novartis seeks tech partners for brave new beyond-the-pill world

Novartis hasn't been shy about digital. The Swiss drugmaker has rolled out app after app to help patients track their symptoms and stay on their drugs. But CEO Joe Jimenez says the company is about to do a lot more than that.

Warning to Takeda, Bayer, Novartis and AstraZeneca: CEO-hunting Sanofi may poach your executives

Those fast-and-furious rumors about Chris Viehbacher's impending ouster at Sanofi? The new round of chatter about Viehbacher's replacement is almost as intense. Bloomberg has a list of healthcare execs said to be up for the job, and they span a who's who of Big Pharma companies.